Related Experiment Videos
Safety of ondansetron.
W M Castle1, A J Jukes, C J Griffiths
1Glaxo Group Research, Greenford, Middlesex, UK.
European Journal of Anaesthesiology. Supplement
|November 1, 1992
Summary
Ondansetron effectively treats nausea and vomiting caused by chemotherapy and surgery. Extensive safety data confirms it is well-tolerated with no drug interactions or impact on postoperative recovery.
Area of Science:
- Pharmacology
- Gastroenterology
Background:
- 5-HT3 receptor antagonists represent a significant advancement in managing emesis.
- Chemotherapy and surgical procedures frequently induce nausea and vomiting, impacting patient recovery.
Purpose of the Study:
- To evaluate the safety and tolerability of ondansetron.
- To assess the efficacy of ondansetron in treating cytotoxic-induced emesis and postoperative nausea and vomiting.
Main Methods:
- Review of safety data from volunteer studies.
- Analysis of non-emesis development studies.
- Examination of clinical trial data for cytotoxic-induced emesis and postoperative nausea and vomiting.
- Assessment of spontaneous case reports.
Main Results:
- Ondansetron is consistently well-tolerated across various study types.
- The drug exhibits an excellent safety profile with no significant adverse events reported.
- No drug interactions with ondansetron have been identified.
- Ondansetron does not interfere with normal postoperative recovery.
Conclusions:
- Ondansetron is a safe and effective antiemetic agent.
- Its favorable safety profile supports its use in managing chemotherapy-induced and postoperative nausea and vomiting.